Navigation Links
Cardiome Announces Management Transition
Date:8/3/2009

NASDAQ: CRME TSX: COM

VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Doug Janzen, formerly President and Chief Business Officer, has been appointed to the role of President and Chief Executive Officer by the Board of Directors, effective immediately. Bob Rieder, formerly Chairman and Chief Executive Officer, has been appointed Executive Chairman of the Board.

"My tenure as CEO has been very satisfying in terms of what we have together accomplished, and I am honoured to have worked closely with so many talented professionals at Cardiome," stated Mr. Rieder. "I am excited about our future as I pass the reigns over to Doug Janzen, and I look forward to working with my fellow Board members and the management team as we continue to build value for Cardiome shareholders."

"Having successfully led Cardiome through more than a decade of growth and transformation, Bob has implemented a thoughtful and deliberate succession process," said Richard Glickman, lead independent director of Cardiome's Board of Directors. "The Board is highly confident that this re-alignment of responsibilities will shepherd in a new chapter in Cardiome's evolution as a world-class drug development company."

"I am honoured to have the opportunity to lead this exceptional organization. We have a fantastic group of dedicated and skilled employees at Cardiome who have succeeded despite the many challenges faced over the past few years, and I am excited about our prospects going forward." stated Mr. Janzen. "I have worked closely with Bob over the past 6 years and look forward to continuing our joint efforts to build Cardiome through this transition and beyond. I want to thank him for his dedication and tremendous contribution to Cardiome, and I wish him well in this next phase of his Cardiome career."

Mr. Rieder, 63, became CEO of Cardiome in March 1998 and Chairman in March 2007. Mr. Janzen, 40, joined Cardiome as Chief Financial Officer in January 2003, and was appointed President and Chief Business Officer in March 2006, at which time he joined the Board of Directors of Cardiome.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.


'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
2. Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
3. Cardiome Reports First Quarter Results
4. Cardiome to Hold Conference Call
5. CardioCareLive.com, First Ever Online Cardiometabolic Conference, Revolutionizes Continuing Medical Education for Cardiovascular Healthcare Professionals
6. Cardiome Reports 2008 Results
7. CardioCareLive, First-Ever Online Cardiometabolic Conference, Debuts Today
8. Noninvasive Medical Technologies to Exhibit at CardioCareLive - A Premier Cardiometabolic Conference
9. Cardiome Discloses Chairman And CEOs Involuntary Share Sale
10. Cardiome Provides Regulatory Update
11. Cardiome To Release Second Quarter Results And Hold Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology: